

Growth Summary and Financial Performance

Jeff Points
Chief Financial Officer

July 31, 2018

Safe Harbor

FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation regarding CSI's growth, future financial measurements, product development and introductions, clinical trials, and market opportunities, are forward-looking statements. These statements involve risks and uncertainties that could cause results differ materially from those projected, including, but not limited to, those described in CSI's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly and annual reports. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this presentation. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this presentation. The forward-looking statements contained in this presentation are made only as of the date of this presentation, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances.

FINANCIAL INFORMATION

This presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by CSI's independent registered accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences, which may be material. In addition, this presentation also includes certain non-GAAP financial measures, such as Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this presentation to the most comparable U.S. GAAP measures for the respective periods can be found in tables in the appendix to this presentation. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for CSI's financial results prepared in accordance with GAAP.

Strong and Stable Business Model

Cash and Liquidity


\$116M in cash and cash equivalents at June 30, 2018

Recurring cash flow generated from operations

\$40M line of credit unused and available

Revenue

(Millions)
CAGR = 12%




Adjusted EBITDA


(Millions)



Gross Margin



Platform for Growth



Growth through geographic expansion and innovation



Organic growth investments are internally funded



R&D investments increase to 14%-17% of revenues in FY21 (12% in FY18)






Leveraging SG&A spend down as a % of revenue



Opportunistic portfolio management

Broadening Value Streams

International and New Products account for approximately 24% of total revenues in FY23



■ OAS Base ■ New Products ■ International

FY21 Financial Goals



CSI Cost Down



Material Cost Reduction Programs



Volume Driven OH Leverage



LEAN Productivity Initiatives

Revenues

- \$300M–\$350M
- CAGR = 11%-17%

Gross Margins

- 78%–80%
- Ongoing cost reduction initiatives

R&D Investments

- Approximately \$50M (14%-17% of revenues)
- CAGR = 25%

Adjusted EBITDA


- 8%–10% of revenue

Net Income

- 3%–5% of revenue


Poised for Significant Long-Term Revenue Growth

Historical Revenue



12%
CAGR

Future Revenue



15%–18%
5-Year CAGR

Appendix: Non-GAAP Financial Measures

To supplement CSI's consolidated condensed financial statements prepared in accordance with GAAP, CSI uses a non-GAAP financial measure referred to as "Adjusted EBITDA" in this presentation. Reconciliations of this non-GAAP measure to the most comparable U.S. GAAP measure for the respective periods can be found in the following table. In addition, an explanation of the manner in which CSI's management uses this measure to conduct and evaluate its business, the economic substance behind management's decision to use this measure, the substantive reasons why management believes that this measure provides useful information to investors, the material limitations associated with the use of this measure and the manner in which management compensates for those limitations is included following the reconciliation table.

| (in thousands) | Year Ended June 30 | | | | |
|---------------------------------------|-----------------------|-------------------|-------------------|-----------------|-----------------|
| | 2014 | 2015 | 2016 | 2017 | 2018 |
| Net income (loss) | \$ (35,290) | \$(32,822) | \$(56,024) | \$(1,792) | \$1,712 |
| Less: Other (income) and expense, net | 1,711 | 71 | (145) | 164 | 390 |
| Less: Provision for income taxes | 90 | 114 | 92 | 86 | 132 |
| Income (loss) from operations | (33,489) | (32,637) | (56,077) | (1,542) | 2,234 |
| Add: Stock-based compensation | 10,928 | 14,718 | 12,977 | 10,354 | 10,302 |
| Add: Depreciation and amortization | 1,367 | 2,321 | 3,917 | 4,135 | 3,934 |
| Adjusted EBITDA | \$(21,194) | \$(15,598) | \$(39,183) | \$12,947 | \$16,470 |

Use and Economic Substance of Non-GAAP Financial Measures Used by CSI and Usefulness of Such Non-GAAP Financial Measures to Investors

CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense and non-cash charges such as stock based compensation. CSI's management uses Adjusted EBITDA to analyze the underlying trends in CSI's business, assess the performance of CSI's core operations, establish operational goals and forecasts that are used to allocate resources and evaluate CSI's performance period over period and in relation to its competitors' operating results. Additionally, CSI's management is evaluated on the basis of Adjusted EBITDA when determining achievement of their incentive compensation performance targets.

CSI believes that presenting Adjusted EBITDA provides investors greater transparency to the information used by CSI's management for its financial and operational decision-making and allows investors to see CSI's results "through the eyes" of management. CSI also believes that providing this information better enables CSI's investors to understand CSI's operating performance and evaluate the methodology used by CSI's management to evaluate and measure such performance.

Appendix: Non-GAAP Financial Measures

The following is an explanation of each of the items that management excluded from Adjusted EBITDA and the reasons for excluding each of these individual items:

-- Stock-based compensation. CSI excludes stock-based compensation expense from its non-GAAP financial measures primarily because such expense, while constituting an ongoing and recurring expense, is not an expense that requires cash settlement. CSI's management also believes that excluding this item from CSI's non-GAAP results is useful to investors to understand the application of stock-based compensation guidance and its impact on CSI's operational performance, liquidity and its ability to make additional investments in the company, and it allows for greater transparency to certain line items in CSI's financial statements.

-- Depreciation and amortization expense. CSI excludes depreciation and amortization expense from its non-GAAP financial measures primarily because such expenses, while constituting ongoing and recurring expenses, are not expenses that require cash settlement and are not used by CSI's management to assess the core profitability of CSI's business operations. CSI's management also believes that excluding these items from CSI's non-GAAP results is useful to investors to understand CSI's operational performance, liquidity and its ability to make additional investments in the company.

Material Limitations Associated with the Use of Non-GAAP Financial Measures and Manner in which CSI Compensates for these Limitations

Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for CSI's financial results prepared in accordance with GAAP. Some of the limitations associated with CSI's use of these non-GAAP financial measures are:

-- Items such as stock-based compensation do not directly affect CSI's cash flow position; however, such items reflect economic costs to CSI and are not reflected in CSI's "Adjusted EBITDA" and therefore these non-GAAP measures do not reflect the full economic effect of these items.

-- Non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles and therefore other companies may calculate similarly titled non-GAAP financial measures differently than CSI, limiting the usefulness of those measures for comparative purposes.

-- CSI's management exercises judgment in determining which types of charges or other items should be excluded from the non-GAAP financial measures CSI uses. CSI compensates for these limitations by relying primarily upon its GAAP results and using non-GAAP financial measures only supplementally. CSI provides full disclosure of each non-GAAP financial measure.

-- CSI uses and detailed reconciliations of each non-GAAP measure to its most directly comparable GAAP measure. CSI encourages investors to review these reconciliations. CSI qualifies its use of non-GAAP financial measures with cautionary statements as set forth above.

CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc.

© 2018 Cardiovascular Systems, Inc.

Sapphire® and OrbusNeich® are trademarks of OrbusNeich Medical, Inc.